This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Merck has also decided to end the favezelimab clinical development program
ALS patients experience neuroinflammation and rapid neurodegeneration
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Subscribe To Our Newsletter & Stay Updated
